98%
921
2 minutes
20
Background: Anticoagulation in patients with intracranial hemorrhage (ICH) and mechanical heart valves is often held for risk of ICH expansion; however, there exists a competing risk of acute ischemic stroke (AIS). Optimal timing to resume anticoagulation remains uncertain.
Methods And Results: We retrospectively studied patients with ICH and mechanical heart valves from 2000 to 2018. The primary outcome was a composite end point of symptomatic hematoma expansion or new ICH, AIS, and intracardiac thrombus up to 30 days post-ICH. The exposure was timing of reinitiation of anticoagulation classified as early (resumed up to 7 days after ICH), late (≥7 and up to 30 days after ICH), and never if not resumed or resumed after 30 days post-ICH. We included 184 patients with ICH and mechanical heart valves (65 anticoagulated early, 100 late, 19 not resumed by day 30 post-ICH). Twelve patients had AIS, 16 new ICH, and 6 intracardiac thromboses. The mean time from ICH to anticoagulation was 12.7 days. Composite outcomes occurred in 12 patients resumed early (18.5%), 14 resumed late (14.0%), and 4 never resumed (21.1%). There was no increased hazard of the composite outcome (hazard ratio [HR], 1.1 [95% CI, 0.2-6.0]), AIS, or worsening or new ICH among patients resumed early versus late. There was no difference in the composite among patients never resumed versus resumed. Patients who never resumed anticoagulation had significantly more severe ICH (median Glasgow Coma Scale: 10.6, 13.9, and 13.9 among those who resumed never, early, and late, respectively; =0.0001), higher in-hospital mortality (56.5%, 0%, and 0%, respectively; <0.0001), and an elevated 30-day AIS risk (HR, 15.9 [95% CI, 1.9-129.7], =0.0098).
Conclusions: In this study of patients with ICH and mechanical heart valves, there was no difference in 30-day thrombotic and hemorrhagic brain-related outcomes when anticoagulation was resumed within 7 versus 7 to 30 days after ICH. Withholding anticoagulation >30 days was associated with severe baseline ICH, higher in-hospital case fatality, and elevated AIS risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179836 | PMC |
http://dx.doi.org/10.1161/JAHA.123.032094 | DOI Listing |
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Multimed Man Cardiothorac Surg
September 2025
Robotic mitral repair is often associated with longer ischaemic and cardiopulmonary bypass times, particularly early in the learning curve. We demonstrate a semi-continuous, three-suture technique for robotic annuloplasty that retains the mechanical principles of traditional interrupted sutures while leveraging the advantages of robotic precision and exposure. The use of pre-knotted sutures minimizes intra-cardiac knot tying, further enhancing procedural efficiency.
View Article and Find Full Text PDFCardiol Young
September 2025
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
The Occlutech Atrial Flow Regulator is a self-expandable double-disc nitinol device with a central fenestration designed to create a calibrated communication across the interatrial septum. It has been used in adult patients with heart failure and pulmonary hypertension. Its use in the paediatric population or adults with CHD has been published in several case reports and case series.
View Article and Find Full Text PDFHeart
September 2025
Department of Biomedical Engineering, CARIM Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with conventional management often applying standardised approaches that struggle to address individual variability in increasingly complex patient populations. Computational models, both knowledge-driven and data-driven, have the potential to reshape cardiovascular medicine by offering innovative tools that integrate patient-specific information with physiological understanding or statistical inference to generate insights beyond conventional diagnostics. This review traces how computational modelling has evolved from theoretical research tools into clinical decision support systems that enable personalised cardiovascular care.
View Article and Find Full Text PDFBackground: During left bundle branch area pacing (LBBAP), several markers of electrical synchrony, (V6 R-wave peak time (RWPT), aVL-RWPT, and the V6-V1 interpeak interval), are commonly used to assess left bundle branch (LBB) capture. Nevertheless, the relationship between these electrocardiographic (ECG) measurements and mechanical synchrony remains poorly understood.
Objective: We aimed to analyze the association between electrical parameters from the paced QRS complex and mechanical performance assessed through 2D strain and myocardial work (MW) indices, following LBBAP implantation.